Related Experiment Video
Updated: May 10, 2026
15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
[Amyotrophic lateral sclerosis: update on etiological treatment]
Lucie Ayach1, Christophe Curti, Marc Montana
1Pharmacie à usage intérieur, Hôpital de la Timone, AP-HM, Marseille, France.
Therapie
|June 19, 2013
Summary
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. Current treatments offer limited survival benefits, necessitating research into novel therapies like stem cells.
Area of Science:
- Neuroscience
- Neurology
- Degenerative Diseases
Context:
- Amyotrophic lateral sclerosis (ALS) is a rare, progressive neurodegenerative disorder impacting motor neurons.
- The disease leads to paralysis and respiratory failure, resulting in a lethal outcome.
- Riluzole is the sole approved medication, offering only a modest survival extension in early stages.
Purpose:
- To review the current landscape of amyotrophic lateral sclerosis (ALS) therapeutics.
- To highlight the limitations of existing treatments and the need for novel approaches.
- To discuss the potential of emerging therapies, including neuroprotective agents and stem cells.
Summary:
- Despite extensive research, the precise mechanisms of ALS remain incompletely understood.
- Numerous clinical trials targeting neuroprotection (antiglutamatergic, antioxidant, antiapoptotic) have failed to improve survival or quality of life.
- Promising results in animal models have not translated to clinical efficacy in humans.
Impact:
- Existing treatments for ALS provide limited therapeutic benefit.
- The failure of conventional neuroprotective agents underscores the need for innovative treatment strategies.
- Ongoing clinical trials exploring stem cells and other novel therapeutics offer future hope for ALS patients.
More Related Videos
10:49Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
04:41Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
Published on: February 24, 2026
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...